Recent news on Cetuximab

RAF engineer denied new cancer drug  -  25 May 2007
Channel 4 News,He has been told that a new drug, Cetuximab, may help but at £7000 for three doses Devon Primary Care Trust said it has been advised it does not represent a

Guidelines on skin reactions to Epidermal Growth Factor Receptor ...  -  25 May 2007
News-Medical.net,The drugs , including erlotinib (Tarceva), cetuximab (Erbitux), and panitumumab (Vectibix) , work by interfering with cell-signaling abnormalities that

Cancer sufferers to be denied drug on NHS  -  May 14, 2007
Daily Mail,The National Institute for Health and Clinical Excellence (Nice) has rejected Erbitux (also known as cetuximab) for cancer sufferers in England and Wales.

NICE turns down Erbitux and defends its record on cancer  -  May 14, 2007
Pharma Times (subscription),NICE, which rules on the drugs that can be prescribed on the NHS in England and Wales, has issued its final draft guidance on Erbitux (cetuximab),

EGFR-Targeted Therapies for Colorectal Cancer Linked to Lower ...  -  May 1, 2007
MedPage Today,All patients had metastatic colorectal cancer and most were enrolled in phase I, II, or III trials of cetuximab (Erbitux) or the investigational agents

Looking Into ImClone's Crystal Ball  -  May 17, 2007
CNBC,CRYSTAL is an acronym, but you won't believe how they stretched to create it: Cetuximab combined with iRinotecan in first line therapY for metaSTatic

NCCN Updates Head and Neck Cancers Guidelines  -  May 22, 2007
Business Wire (press release),Cetuximab (Erbitux®, ImClone/Bristol-Myers Squibb) plus concurrent radiation therapy has been added as a systemic therapy option for unresectable and

KRAS Mutation Linked with Poor Response to Colorectal Cancer Treatment  -  May 1, 2007
Cancerpage.com,NEW YORK APR 30, 2007 (Reuters Health) - The presence of the KRAS mutation in metastatic colorectal cancer is associated with a poor response to cetuximab

World's Cancer Patients Face Inequities in Access to Newer Drugs  -  May 10, 2007
Atlanta Journal Constitution (subscription),The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found.

UK Lags Behind In New Cancer Drug Uptake And Survival  -  May 11, 2007
Medical News Today,..."The greatest differences in uptake were noted for the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed."

NICE: failure to recommend Erbitux adds more fuel to fire against ...  -  May 15, 2007
Pharmaceutical Business Review...'Content NICE has issued final draft guidance on the use of ImClone System/Merck KGaA/ Bristol-Myers Squibb’s Erbitux (cetuximab), recommending against its

Petition for man to get cancer drug  -  May 9, 2007
This Is Lancashire,Mr Booth, aged 44, has been told by medical experts that the drug, Cetuximab, is his only chance of a longer life. But the family, including wife, Alison,

Petition backs fight for ‘wonder drug’  -  May 8, 2007
Bolton News,Mr Booth, aged 44, from Daubhill, Bolton, has been told by medical experts that the drug, Cetuximab, is his only chance of a longer life.

Patients denied drug for cancer of the head and neck  -  May 14, 2007
Therapeutics Daily (subscription) (press release),The National Institute for Health and Clinical Excellence (NICE) is set to reject Erbitux (cetuximab) for cancer sufferers in England and Wales.

Head and neck cancer drug not available on NHS  -  May 14, 2007
Earthtimes.orgLONDON - The National Institute for Health and Clinical Excellence (Nice) has decided to reject the drug Erbitux (cetuximab) for people suffering from head

Crucial cancer trial will go ahead in Canada  -  May 11, 2007
Globe and Mail,Erbitux, the trade name for cetuximab, is a monoclonal antibody that shrinks tumours in some patients and delays tumour growth, especially when used as a

Patients around the world face stark inequalities in access to ...  -  May 11, 2007
News-Medical.net,Dr Jonsson said: "The greatest differences in uptake were noted for the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and

A Global Comparison Of Patients' Access To New And Better Cancer ...  -  May 10, 2007
Medical News Today (press release),Dr Jönsson said: "The greatest differences in uptake were noted for the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and

Gene Mutation Linked with Poor Response to Erbitux® in Patients ...  -  May 8, 2007
Cancer Consultants (press release),Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. British Journal of Cancer.

CMS Cites EPO's Bad Rap In Plan To Curtail Reimbursement  -  May 15, 2007
BioWorld Online,Inc.) or antibodies directed against the epidermal growth factor receptor like Erbitux (cetuximab, ImClone Systems Inc. and Bristol-Myers Squibb Co.

Report finds "low and slow" uptake of new anticancers in UK  -  May 11, 2007
Pharma Times (subscription),The most acute disparities were seen with the colorectal and lung cancer drugs bevacizumab (Avastin, Roche), cetuximab (Erbitux, Bristol-Myers Squibb/Merck

Australian scientists directly target cancer cells  -  May 11, 2007
People's Daily Online,The biggest differences were seen in four new colorectal and lung cancer drugs Avastin, or bevacizumab; Erbitux, or cetuximab; Tarceva, or erlotinib;

Experts warn of global gap in cancer treatment  -  May 10, 2007
Scientific AmericanThe biggest differences were seen in four new colorectal and lung cancer drugs - bevacizumab (Avastin); cetuximab (Erbitux); erlotinib (Tarceva); (Alimta);

Experts warn of global gulf in cancer treatment  -  May 9, 2007
Reuters South Africa,The biggest differences were seen in four new colorectal and lung cancer drugs -- Avastin, or bevacizumab; Erbitux, or cetuximab; Tarceva, or erlotinib;

‘Stark inequalities’ in access to cancer drugs  -  May 9, 2007
MSNBCThe biggest differences were seen in four new colorectal and lung cancer drugs — Avastin, or bevacizumab; Erbitux, or cetuximab; Tarceva, or erlotinib;

NZ lags in access to life-saving drugs  -  May 9, 2007
TVNZ,The biggest differences were seen in four new colorectal and lung cancer drugs - Avastin, or bevacizumab; Erbitux, or cetuximab; Tarceva, or erlotinib;

Lonza plans to commercially produce emerging class of drugs  -  May 10, 2007
DrugResearcher.com,Genentech/Biogen Idec's lymphoma treatment Rituxan (infliximab) and colorectal cancer drug Erbitux (cetuximab) sold in Europe by Merck KGaA.

Low Levels of Magnesium Associated with EGFR Antibodies in ...  -  May 3, 2007
Cancer Consultants (press release),Erbitux® (cetuximab) and Vectibix™ (panitumumab) are two agents that target EGFR and have demonstrated significant anticancer activity in the treatment of

Magnesium loss In patients given monoclonal antibodies  -  May 3, 2007
News-Medical.net,97% of patients with cancer treated with monoclonal antibodies-cetuximab, matuzumab, or panitumumab-that target the epidermal growth factor receptor (EGFR)

Magnesium Loss In Patients Given Monoclonal Antibodies  -  May 2, 2007
innovations report,97% of patients with cancer treated with monoclonal antibodies—cetuximab, matuzumab, or panitumumab—that target the epidermal growth factor receptor (EGFR)

Magnesium Loss in Patients Given Monoclonal Antibodies  -  May 1, 2007
PharmaLive.com (press release),LONDON, April 30, 2007-97% of patients with cancer treated with monoclonal antibodies—cetuximab, matuzumab, or panitumumab—that target the epidermal growth

Bristol-Myers Squibb relieved to see Plavix back on track  -  Apr 27, 2007
Pharma Times (subscription),...rising 29% to $226 million and Reyataz (atazanavir) up 27% to $263 million, while sales of cancer drug Erbitux (cetuximab) climbed 16% to $160 million.

Family’s £20000 fight to prolong father’s life  -  Apr 25, 2007
This Is Lancashire,A PCT spokesman said: "The latest guidance to the NHS from the National Institute for Health and Clinical Excellence (NICE) said that Cetuximab was not an

Cetuximab and Irinotecan Combination Increases Survival in Metastatic  -  Apr 20, 2007
WebWire (press release),LOS ANGELES - A phase III trial of 1298 colorectal cancer patients has found that a combination of the drugs cetuximab (Erbitux) and irinotecan showed a

KRAS Mutation a Strong Predictor of Response to Cetuximab Therapy ...  -  Apr 19, 2007
DG NewsIt has been hypothesised that the presence of a genetic variance known as a KRAS could predict a patient's response to cetuximab.

Genes And Biomarkers That Allow Doctors To Choose The Right ...  -  Apr 23, 2007
Medical News Today (press release),Mutations in the KRAS oncogene could predict a lack of response to the drug cetuximab in patients with colorectal tumors. For those with the mutations,

Cetuximab Improves Overall Survival In Advanced Colorectal Cancer  -  Apr 17, 2007
Medical News Today,Cetuximab (Erbitux), a monoclonal antibody which targets the epidermal growth factor receptor (EGFR), significantly improved overall survival in patients

AACR: Cetuximab Shows Survival Edge as Third-Line Colorectal ...  -  Apr 17, 2007
MedPage Today,LOS ANGELES, April 17 -- Cetuximab (Erbitux) extended median survival by about six weeks as a third-line monotherapy for refractory metastatic colorectal

Study the First to Show Survival Benefits of Cetuximab in Patients ...  -  Apr 17, 2007
DG NewsLOS ANGELES, CA -- April 17, 2007 -- For the first time, a study has demonstrated a survival benefit for cetuximab in patients with colorectal cancer who

Mixed result for cetuximab in colon cancer  -  Apr 17, 2007
United Press InternationalDerek Jonker, assistant professor of medicine at the University of Ottawa, said that cetuximab appeared to extend progression-free survival by about six

Cetuximab-Irinotecan Improves Progression-Free Survival and ...  -  Apr 17, 2007
DG NewsLOS ANGELES, CA -- April 17, 2007 -- Combining cetuximab with irinotecan as a chemotherapeutic regimen for patients with advanced colorectal cancer who have

Cetuximab and irinotecan combination increases survival in ...  -  Apr 17, 2007
Cancer Focus,By the end of the study, a significantly larger number of patients who received the combination of cetuximab, an antibodyterm against the epidermal growth

ImClone Systems Showcases Extensive Research and Development ...  -  Apr 19, 2007
PharmaLive.com (press release),Important ERBITUX(R) (cetuximab) clinical data were the focus of two back-to-back oral presentations leading off the "Breakthroughs in Clinical Research"

Combination boosts progression free survival  -  Apr 19, 2007
Cancerfacts.com,..."These data confirm that, despite a moderate increase in side effects, cetuximab is a key therapeutic agent in the optimal treatment of advanced colorectal

ERBITUX And Disease Control In Metastatic Colorectal Cancer Patients  -  Apr 17, 2007
eMaxHealth.com,ERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the

ImClone Cancer Drug Trials Mixed But Encouraging  -  Apr 16, 2007
Reuters.uk,An international trial involving 1300 patients found that a combination of Erbitux, also known as cetuximab, and chemotherapy drug irinotecan significantly

Bristol-Myers Squibb Reports Progression-Free Survival In ...  -  Apr 16, 2007
Trading Markets,...open-label, multi-center Phase III trial - comparing ERBITUX (Cetuximab) plus irinotecan to irinotecan alone in patients with metastatic colorectal

Randomized Phase III Trial Showed ERBITUX Significantly Improved ...  -  Apr 16, 2007
PR Newswire (press release),About ERBITUX(R) (Cetuximab) ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface

Merck KGaA: Erbitux Meets Primary Endpoint in First-Line Phase III ...  -  Apr 4, 2007
PipelineReview.com (press release),Merck KGaA announced today that a first-line Phase III study of Erbitux(R)(cetuximab) combined with platinum-based chemotherapy met the primary endpoint of

No Survival Benefit with Erbitux in Pancreatic Cancer  -  Apr 11, 2007
Cancerpage.com,BOSTON APR 10, 2007 (Reuters) - ImClone Systems Inc. said on Tuesday that a late-stage trial of Erbitux (cetuximab) failed to extend survival in patients

ImClone Systems, Bristol-Myers Say ERBITUX Phase III Study Fails ...  -  Apr 10, 2007
Trading Markets,...(BMY | charts | news | PowerRating), on Tuesday said that the Phase III study of ERBITUX or Cetuximab plus gemcitabine in patients with locally advanced

Erbitux Increases Overall Survival For Head And Neck Cancer Patients  -  Apr 7, 2007
Medical News Today,Erbitux (Cetuximab), a new drug which is used in combination with chemotherapy, increases overall survival in patients with recurrent and/or metastatic

ImClone Systems Inc. Breaks Out To A 10 1/2 Month High  -  Apr 5, 2007
Trading Markets,...charts | news | PowerRating) on Wednesday revealed first line Phase III study of ERBITUX, Cetuximab, in combination with platinum-based chemotherapy.

Merck KGaA shares gain on Erbitux drug success  -  Apr 4, 2007
ReutersN: Quote, Profile , Research) on Wednesday said a first line Phase III study of Erbitux (Cetuximab) combined with chemotherapy met the main goal of

ImClone, Bristol-Myers Say Erbitux Meets Endpoint  -  Apr 4, 2007
Reuters.uk,N: Quote, Profile , Research) on Wednesday said a first line Phase III study of Erbitux (Cetuximab) combined with platinum-based chemotherapy met the

ImClone, Bristol-Myers say Erbitux meets endpoint  -  Apr 3, 2007
ReutersN: Quote, Profile, Research) on Wednesday said a first line Phase III study of Erbitux (Cetuximab) combined with platinum-based chemotherapy met the primary

Spread Of Breast Cancer Driven By A Genetic 'Gang Of 4'  -  Apr 15, 2007
Medical News Today (press release),The researchers are exploring clinical testing of combination therapy with the drugs - cetuximab (trade name Erbitux) and celecoxib (Celebrex) - to treat

Patients may have to pay fortunes for cancer drugs - professor  -  Mar 30, 2007
Pharma Times (subscription),He claimed that Roche's Avastin (bevacizumab) and Tarceva (erlotinib), GlaxoSmithKline's Tykerb and ImClone's Erbitux (cetuximab) would be some of the drugs

Four genes found to drive spread of breast cancer to the lungs  -  Apr 13, 2007
News-Medical.net,The researchers are exploring clinical testing of combination therapy with the drugs, cetuximab (trade name Erbitux) and celecoxib (Celebrex),

A Genetic 'Gang of 4' Drives Spread of Breast Cancer  -  Apr 12, 2007
PharmaLive.com (press release),The researchers are exploring clinical testing of combination therapy with the drugs—cetuximab (trade name Erbitux) and celecoxib (Celebrex)—to treat breast

Four genes that drive the spread of breast cancer identified  -  Apr 12, 2007
DailyIndia.com,The researchers are studying clinical testing of combination therapy with the drugs, cetuximab (trade name Erbitux) and celecoxib (Celebrex),

A Genetic 'Gang Of 4' Drives Spread Of Breast Cancer  -  Apr 11, 2007
Science Daily (press release)The researchers are exploring clinical testing of combination therapy with the drugs--cetuximab (trade name Erbitux) and celecoxib (Celebrex)--to treat

NEWS RELEASE  -  Apr 23, 2007
Financial News USA (press release),Important ERBITUX® (cetuximab) clinical data were the focus of two back-to-back oral presentations leading off the "Breakthroughs in Clinical Research"

New Study Proves Cancer Metastasis Can Be Stopped  -  Apr 12, 2007
Playfuls.com,Researchers say that metastasis of breast cancer are already attacked with a combination of cetuximab (trade name Erbitux) and celecoxib (Celebrex).

Metastasis genes identified  -  Apr 11, 2007
Scientist,Both cetuximab and celecoxib are currently in clinical testing for an array of cancers, including breast, lung, and colon; celecoxib, also known as Celebrex

Personalising cancer care  -  Apr 21, 2007
Health24.com,In another study, French researchers said they found that mutations in the KRAS oncogene could predict a lack of response to the drug cetuximab in

Merck's Erbitux increases survival in metastatic colorectal cancer ...  -  Apr 18, 2007
SpiritIndia,Data presented at this year’s American Association for Cancer Research (AACR) meeting show that Merck KGaA’s targeted cancer therapy Erbitux® (cetuximab)

Mixed Results in Erbitux Colon Cancer Trial  -  Apr 17, 2007
Cancerpage.com,Researchers said a 1300-patient trial found that a combination of Erbitux, also known as cetuximab, and chemotherapy drug irinotecan significantly improved

Erbitux Studies Provide Conflicting Data  -  Apr 17, 2007
Dog Flu Diet and Diseases,In one trial of 1300 patients, Erbitux, also known as cetuximab, and chemotherapy significantly improved the amount of time that a person lived without

Merck KGaA's Erbitux ups survival 50% in colorectal cancer  -  Apr 17, 2007
Pharma Times (subscription),Merck KGaA's targeted cancer therapy Erbitux (cetuximab) has been shown to significantly prolong progression-free survival and increase overall response

ImClone Systems Cancer Drug ERBITUX Shows Higher Secondary ...  -  Apr 16, 2007
Trading Markets,...(BMY | charts | news | PowerRating) on Monday said results from the EPIC study, which compares ERBITUX or Cetuximab plus chemotherapy drug irinotecan to

Novel EGFR Antibody Outperforms Cetuximab In Mouse Model Of Lung ...  -  Jan 30, 2007
Medical News Today (press release),Several of these antibodies have reached the market, including cetuximab (Erbitux®, ImClone Systems), which targets the epidermal growth factor receptor

Reducing Risks of Infusion Related Reactions in Targeted Cancer ...  -  Jan 30, 2007
PharmiWeb.com (press release),Adding a corticosteroid to antihistamine prophylaxis almost halved the number of reactions seen with cetuximab (50 vs 92). Cetuximab is an IgG1 recombinant

Merck KGaA Seeks Approval for Erbitux for Colorectal Cancer in Japan  -  Feb 6, 2007
PipelineReview.com (press release),The Japanese submission was based on data from two European studies – BOND (Bowel Oncology with Cetuximab Antibody)(4) and MABEL (Monoclonal Antibody

More drugs added to colon-cancer guide  -  Jan 29, 2007
United Press InternationalNCCN further revised the guidelines to include the drug panitumumab -- Amgen's Vectibix -- as an alternative to cetuximab after first or second progression

NCCN Updates Colon Cancer Guidelines  -  Jan 29, 2007
PharmaLive.com (press release),The combination regimens of fluorouracil, leucovorin and irinotecan (Camptosar, Pfizer) (known as FOLFIRI) + cetuximab and irinotecan + cetuximab were added

Dr Reddy's could join race for Merck KGaA's generic unit  -  Feb 5, 2007
Pharma Times (subscription),...to the Japanese Pharmaceuticals and Medical Devices Agency for the use of Erbitux (cetuximab) in treating patients with advanced colorectal cancer.

Politicians shouldn't meddle in NHS funding, UK public says  -  Jan 29, 2007
Pharma Times (subscription),...drug Erbitux (cetuximab) should not be available on the NHS - said that it did not understand the cost framework used by NICE to come to its decision.

Microsatellite Instability, EGFR Testing, and FISH  -  Feb 2, 2007
Medscape (subscription)...[1] This is one of those examples of a molecular factor for which specific targeted therapies have been developed -- in this case cetuximab, a monoclonal

Red tape hampers cancer fight  -  Feb 5, 2007
ic Wales,...this year's campaign for low-dose brachytherapy for prostate cancer patients and the ongoing battle for other cancer drugs, such as Erbitux (cetuximab)

ImClone Systems Incorporated and Bristol-Myers Squibb Announce ...  -  Feb 4, 2007
PR Newswire (press release),About ERBITUX (Cetuximab) ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of

MedImmune rebuffs shareholder suggestion of a sale  -  Feb 19, 2007
Pharma Times (subscription),...at the end of last year, having ousted the board and accused management of failing to make the most of the company's cancer drug Erbitux (cetuximab).

Cancer bill to soar as survival rate increases  -  Feb 6, 2007
ic Wales,...refusing NHS funding for the use of Erbitux (cetuximab), in combination with radiotherapy, for the treatment of locally advanced head and neck cancer.

Funding can depend on where you live  -  Feb 5, 2007
ic Wales,Cetuximab for colorectal cancer – eight patients at a cost of £60000 per annum. Bortezomib (Velcade), for multiple myeloma – one patient at a cost of £10000

Gut Research Yields New Anti-Cancer Approach  -  Feb 5, 2007
Medical News Today (press release),...irinotecan) and antibodies (bevacizumab, cetuximab). Once again, response rates of current drugs are low (less than 30 percent as single agents).

ImClone Systems Incorporated and Bristol-Myers Squibb Announce ...  -  Feb 5, 2007
Drug Newswire (press release),Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the use of ERBITUX(R) (Cetuximab) in treating patients with advanced colorectal cancer.

ImClone Systems Incorporated and Bristol-Myers Squibb Announce ...  -  Feb 4, 2007
Yahoo! News (press release)...the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the use of ERBITUX® (Cetuximab) in treating patients with advanced colorectal cancer.

New drug may have saved my dad’s life  -  Feb 2, 2007
Lancashire Evening Telegraph,Jeff Fay, 49, said he would have been standing alongside campaigners who this month lost their appeal for cetuximab if his father, James, was still alive.

Gut Research Yields New Cancer Approach  -  Feb 2, 2007
Media Newswire (press release),...irinotecan ) and antibodies ( bevacizumab, cetuximab ). Once again, response rates of current drugs are low ( less than 30 percent as single agents ).

Ivrea Pharmaceuticals Appoints Daniel S. Lynch as President and ...  -  Feb 2, 2007
Drug Newswire (press release),...helping to restore the company's reputation and receive FDA approval of ERBITUX(R) (Cetuximab), an important and novel treatment for cancer patients.

Edmund Tirbutt’s overview of the world of small group private ...  -  Feb 15, 2007
Health Insurance and Protection Magazine,New cancer drugs highlighted as being due to come on the market during 2007 were: Avastin and Cetuximab for use in bowel cancer before it spreads;

Exelixis Appoints Jose Baselga, MD, a Leading Expert in Oncology ...  -  Jan 30, 2007
Drug Newswire (press release),He has made significant contributions to the clinical development of several approved targeted cancer therapies, including trastuzumab, cetuximab,

Octreotide of No Benefit in Advanced Liver Cancer  -  Jan 26, 2007
Cancerpage.com,...and others) or monoclonal antibodies against vascular endothelial growth factor or epidermal growth factor receptor (bevacizumab, cetuximab and others).

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional